UPDATE 1-Bristol raises 2016 forecast after first-quarter earnings beat

April 28 (Reuters) - Bristol-Myers Squibb ratcheted up its 2016 profit view after trouncing first-quarter sales and earnings forecasts on strong demand for its new Opdivo immuno-oncology drug and Eliquis blood clot preventer.